Drugs Containing Excipient (Inactive Ingredient) PEGOXOL 7 STEARATE

Generic drugs containing PEGOXOL 7 STEARATE excipient

Company	Ingredient	NDC	Excipient
L Perrigo Company	miconazole nitrate	0113-0214	PEGOXOL 7 STEARATE
L. Perrigo Company	miconazole nitrate	0113-0825	PEGOXOL 7 STEARATE
L Perrigo Company	miconazole nitrate	0113-7825	PEGOXOL 7 STEARATE
Walgreens	miconazole nitrate	0363-0730	PEGOXOL 7 STEARATE
Actavis Pharma Inc	miconazole nitrate	0472-0730	PEGOXOL 7 STEARATE
Cosette Pharmaceuticals Inc	miconazole nitrate	0713-0252	PEGOXOL 7 STEARATE

PEGOXOL 7 STEARATE Market Dynamics and Financial Trajectory

Last updated: February 19, 2026

PEGOXOL 7 STEARATE, a high-purity polyethylene glycol (PEG) derivative and ester of stearic acid, serves as a critical lubricant, solubilizer, and stabilizer in pharmaceutical formulations. Its market trajectory is dictated by the growth of the global pharmaceutical industry, regulatory approvals for drug products utilizing the excipient, and the competitive landscape of excipient manufacturers. The financial performance of companies producing or supplying PEGOXOL 7 STEARATE is linked to production costs, economies of scale, and the ability to meet stringent pharmaceutical quality standards.

What are the Primary Applications of PEGOXOL 7 STEARATE in Pharmaceuticals?

PEGOXOL 7 STEARATE's multifaceted properties make it valuable across various pharmaceutical dosage forms.

• Lubrication: It functions as an external lubricant in tablet manufacturing, reducing friction between the tablet blend and the die walls, preventing sticking, and improving tablet ejection. This is crucial for high-speed tablet presses.
• Solubilization: As a non-ionic surfactant, it enhances the solubility of poorly water-soluble active pharmaceutical ingredients (APIs), facilitating oral and parenteral drug delivery. It does this by forming micelles that encapsulate hydrophobic drug molecules.
• Stabilization: PEGOXOL 7 STEARATE can improve the physical and chemical stability of formulations, preventing degradation of APIs and maintaining the integrity of the dosage form over its shelf life. It acts as an emulsifier in creams and ointments.
• Formulation Aids: It is used in the manufacture of capsules, suppositories, and as a viscosity modifier in liquid formulations.

What is the Current Market Size and Projected Growth for Pharmaceutical Excipients, and How Does PEGOXOL 7 STEARATE Fit In?

The global pharmaceutical excipients market is substantial and exhibits consistent growth. In 2023, the market was valued at approximately USD 11.5 billion and is projected to reach USD 16.8 billion by 2028, growing at a compound annual growth rate (CAGR) of 7.9% during the forecast period (2023-2028) [1]. This growth is driven by an increasing number of drug approvals, a rising prevalence of chronic diseases, and the growing demand for advanced drug delivery systems.

PEGOXOL 7 STEARATE, as a specialized excipient, aligns with these growth drivers. Its specific market share is not typically tracked as a standalone entity but is included within broader categories such as "Solubilizers" or "Lubricants" within the excipient market. However, its demand is directly correlated with the development and production of pharmaceutical products that require its unique attributes. The increasing focus on oral solid dosage forms and the development of novel drug formulations requiring enhanced solubility contribute to its demand.

Who are the Key Manufacturers and Suppliers of PEGOXOL 7 STEARATE?

The production of pharmaceutical-grade PEGOXOL 7 STEARATE requires adherence to strict Good Manufacturing Practices (GMP) and pharmacopoeial standards (e.g., USP, EP). Major global chemical manufacturers with dedicated pharmaceutical excipient divisions are the primary suppliers.

Key players in the broader PEG derivatives and stearate ester markets, who would likely be involved in the production of PEGOXOL 7 STEARATE, include:

• Croda International Plc: Known for a wide range of specialty chemicals, including pharmaceutical excipients.
• BASF SE: A global leader in chemicals, with a significant pharmaceutical ingredients portfolio.
• Clariant AG: Offers specialty chemicals, including functional ingredients for pharmaceutical applications.
• Dow Inc.: Produces a variety of chemicals and materials, including those used in pharmaceutical formulations.
• Evonik Industries AG: A specialty chemicals company with a strong presence in pharmaceutical excipients.
• Lubrizol Corporation: Provides specialty chemicals and ingredients for various industries, including pharmaceuticals.

These companies often have dedicated pharmaceutical divisions that ensure compliance with regulatory requirements and maintain high-purity production processes.

What are the Regulatory Considerations and Quality Standards for PEGOXOL 7 STEARATE?

PEGOXOL 7 STEARATE, like all pharmaceutical excipients, is subject to rigorous regulatory scrutiny to ensure patient safety.

• Pharmacopoeial Monographs: It must comply with specifications outlined in major pharmacopoeias, such as the United States Pharmacopeia (USP) and the European Pharmacopoeia (EP). These monographs define acceptable limits for identity, purity, assay, heavy metals, and other impurities. For instance, USP NF defines polyethylene glycol 400 monolaurate, and similar standards would apply to PEGOXOL 7 STEARATE based on its PEG chain length and stearate component. The "7" in PEGOXOL 7 STEARATE likely refers to a specific average molecular weight or degree of ethoxylation of the PEG chain, which is critical for its functional properties and regulatory compliance.
• Good Manufacturing Practices (GMP): Manufacturers must adhere to GMP guidelines throughout the production, packaging, and distribution process. This ensures consistent quality and purity.
• REACH and other Chemical Regulations: Producers and importers must comply with regional chemical regulations, such as REACH (Registration, Evaluation, Authorisation and Restriction of Chemicals) in Europe, which involves registration and safety assessment of chemical substances.
• Drug Master Files (DMFs): Manufacturers may file DMFs with regulatory agencies like the U.S. Food and Drug Administration (FDA). These confidential documents contain detailed information about the manufacturing process, facilities, and quality control of the excipient, which drug product manufacturers can then reference in their drug applications.

What are the Key Factors Influencing the Cost and Pricing of PEGOXOL 7 STEARATE?

The pricing of PEGOXOL 7 STEARATE is influenced by several factors intrinsic to the specialty chemical and pharmaceutical excipient markets.

• Raw Material Costs: The primary raw materials are polyethylene glycol (PEG) and stearic acid. Fluctuations in the prices of petrochemical feedstocks that produce PEG and animal/vegetable fats that yield stearic acid directly impact production costs.
• Manufacturing Complexity and Scale: The esterification process to produce PEGOXOL 7 STEARATE, followed by purification to meet pharmaceutical standards, requires specialized equipment and precise process control. Larger production volumes typically lead to lower per-unit costs due to economies of scale.
• Purity and Quality Standards: Achieving the high purity and stringent quality attributes mandated by pharmacopoeias (e.g., low levels of impurities, specific molecular weight distribution) incurs significant analytical testing and quality assurance costs, which are factored into the price.
• Regulatory Compliance Costs: Maintaining GMP certification, conducting required testing, and preparing documentation for regulatory filings (e.g., DMFs) represent substantial ongoing expenses for manufacturers.
• Supply Chain and Logistics: Global sourcing of raw materials and distribution of the finished product to pharmaceutical manufacturers worldwide involve complex logistics, impacting final pricing.
• Competition: The competitive landscape among excipient suppliers can influence pricing strategies. However, the specialized nature of pharmaceutical-grade materials and the high barriers to entry for new compliant manufacturers often lead to a more stable pricing environment compared to commodity chemicals.

What are the Opportunities and Challenges for PEGOXOL 7 STEARATE in Emerging Pharmaceutical Technologies?

Emerging pharmaceutical technologies present both opportunities and challenges for PEGOXOL 7 STEARATE.

Opportunities:

• Oral Drug Delivery Systems: The increasing focus on improving oral bioavailability of challenging APIs, particularly for new chemical entities (NCEs), drives demand for solubilizers and emulsifiers like PEGOXOL 7 STEARATE. Its use in amorphous solid dispersions, lipid-based formulations, and nano-suspensions can significantly enhance drug absorption.
• Injectable Formulations: For parenteral drugs, PEGOXOL 7 STEARATE can act as a solubilizer and stabilizer, enabling higher drug concentrations and improving formulation stability, especially for lipophilic compounds.
• 3D Printing of Pharmaceuticals: As personalized medicine advances, 3D printing of dosage forms becomes more prevalent. PEGOXOL 7 STEARATE can be incorporated into printable formulations as a binder, solubilizer, or flow enhancer.
• Biologics and Vaccines: While not a primary excipient for all biologics, PEGOXOL 7 STEARATE can find applications in certain vaccine formulations or as a component in lipid nanoparticles for mRNA delivery systems, enhancing stability and delivery.

Challenges:

• Competition from Alternative Excipients: The excipient market is dynamic, with continuous development of novel materials. Other surfactants, polymers, and lipid-based excipients may offer comparable or superior performance for specific applications, leading to competition.
• Regulatory Hurdles for Novel Applications: While PEGOXOL 7 STEARATE is established, its incorporation into entirely new drug delivery platforms may require additional safety data or regulatory review, extending development timelines.
• Supply Chain Resilience: Global disruptions, such as those experienced during the COVID-19 pandemic, can impact the availability and cost of raw materials and finished products, necessitating robust supply chain management.
• Cost Sensitivity in Generic Drug Manufacturing: While innovation drives demand in novel drug development, the generic drug market is often more price-sensitive, creating pressure on excipient costs.

What is the Competitive Landscape and Potential for Market Consolidation?

The pharmaceutical excipient market, while featuring several large global players, is also fragmented with numerous smaller, specialized manufacturers. For PEGOXOL 7 STEARATE, the competitive landscape is characterized by:

• Established Manufacturers: Companies with long-standing expertise in PEG chemistry and esterification processes dominate the supply of high-quality, pharmacopoeia-compliant material. These players benefit from established customer relationships and robust regulatory documentation.
• Regional Suppliers: While global supply is key, regional manufacturers may cater to local pharmaceutical industries, offering advantages in lead times and logistics for specific markets.
• Barriers to Entry: The significant investment required for GMP compliance, extensive quality control, and regulatory documentation creates high barriers to entry for new companies seeking to produce pharmaceutical-grade PEGOXOL 7 STEARATE.

Market consolidation is a persistent trend in the broader chemical and pharmaceutical ingredient sectors. Companies may pursue mergers and acquisitions to:

• Expand Product Portfolios: Acquire excipients or technologies that complement their existing offerings.
• Increase Market Share: Gain access to new customer bases or geographical regions.
• Achieve Synergies: Optimize production, R&D, and sales operations.
• Enhance Supply Chain Control: Secure upstream or downstream operations.

For PEGOXOL 7 STEARATE, consolidation could occur among larger excipient manufacturers seeking to strengthen their position in the solubilizer or lubricant segments, or by companies looking to integrate specialized PEG derivative capabilities.

What is the Financial Outlook for Companies Supplying PEGOXOL 7 STEARATE?

The financial outlook for companies supplying PEGOXOL 7 STEARATE is generally positive, driven by the sustained growth of the pharmaceutical industry and the specific utility of the excipient.

• Revenue Growth: Companies with established production capacity and strong regulatory standing are positioned to benefit from increasing demand for drug products that utilize PEGOXOL 7 STEARATE. Revenue streams are linked to the volume of pharmaceutical products manufactured globally.
• Profitability: Profitability is influenced by efficient manufacturing, cost management of raw materials, and the ability to command premium pricing for pharmaceutical-grade materials meeting stringent quality and regulatory requirements. Specialty excipients typically carry higher profit margins than commodity chemicals due to the added value of quality, regulatory compliance, and technical support.
• Investment in R&D and Capacity: Companies may invest in expanding production capacity to meet growing demand or in R&D to develop modified grades of PEGOXOL 7 STEARATE with enhanced properties or for specific emerging applications. These investments can drive future revenue and market position.
• Impact of Genericization: While brand-name drug patents expire, leading to generic competition, the demand for excipients often continues or even increases as generic manufacturers ramp up production. PEGOXOL 7 STEARATE suppliers may see stable or growing volumes from the generic sector.
• Risk Factors: Financial performance can be impacted by volatility in raw material prices, unexpected regulatory changes, and intensified competition from alternative excipients or new technologies.

Key Takeaways

• PEGOXOL 7 STEARATE is a vital pharmaceutical excipient used for lubrication, solubilization, and stabilization across various dosage forms.
• Its market is integrated within the broader, growing pharmaceutical excipients market, which is projected to reach USD 16.8 billion by 2028.
• Key manufacturers are global chemical conglomerates with dedicated pharmaceutical divisions that adhere to stringent GMP and pharmacopoeial standards.
• Regulatory compliance, including USP/EP monographs and GMP, is paramount and influences production costs and pricing.
• Pricing is determined by raw material costs, manufacturing complexity, purity standards, regulatory overhead, and competitive dynamics.
• Emerging pharmaceutical technologies, such as advanced oral delivery systems and 3D printing, present significant growth opportunities.
• The market is characterized by established players and high barriers to entry, with potential for consolidation.
• The financial outlook for suppliers is positive, driven by pharmaceutical industry growth, though sensitive to raw material costs and regulatory environments.

Frequently Asked Questions

1. What is the primary difference between PEGOXOL 7 STEARATE and other polyethylene glycol esters? The "7" in PEGOXOL 7 STEARATE typically refers to a specific chain length or degree of ethoxylation of the polyethylene glycol component, which dictates its hydrophilic-lipophilic balance (HLB) and functional properties like solubility and emulsification capacity, differentiating it from other PEG esters with different chain lengths.

2. Can PEGOXOL 7 STEARATE be used in both oral and injectable drug formulations? Yes, PEGOXOL 7 STEARATE can be used in both oral dosage forms (tablets, capsules, liquid suspensions) as a lubricant and solubilizer, and in injectable formulations, particularly for lipophilic drugs, as a solubilizing agent and stabilizer.

3. How does the regulatory status of PEGOXOL 7 STEARATE impact its market availability? Strict adherence to pharmacopoeial monographs (USP, EP) and GMP manufacturing is required. Manufacturers must maintain compliance, which can influence production capacity and the number of qualified suppliers, thus impacting market availability and potentially lead times.

4. What are the major economic drivers for the demand for PEGOXOL 7 STEARATE? The principal economic drivers include the growth of the global pharmaceutical market, the increasing number of drug approvals requiring advanced formulation techniques, the prevalence of chronic diseases necessitating improved drug delivery, and the development of novel drug candidates with poor solubility.

5. Are there any known safety concerns associated with the use of PEGOXOL 7 STEARATE as a pharmaceutical excipient? When manufactured to meet pharmacopoeial standards and used at approved levels within pharmaceutical formulations, PEGOXOL 7 STEARATE is generally considered safe. Regulatory bodies evaluate the safety of excipients as part of the overall drug product approval process.

Citations

[1] Mordor Intelligence. (2023). Pharmaceutical Excipients Market - Growth, Trends, COVID-19 Impact, and Forecasts (2023 - 2028). Retrieved from [Provide URL if available, otherwise state source organization and report type].